BioSyent In-Licenses Endocrinology Product for Canada

MISSISSAUGA, Ontario, June 12, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. ("BioSyent", "the Company", TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. ("Bio

GlobeNewswireJun 12 09:00 ET

BioSyent Inc. Reports Strong Q1 Financial Growth

TipRanksMay 16 19:07 ET

BioSyent Declares Second Quarter 2024 Dividend

MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. ("BioSyent", "the Company", TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend

GlobeNewswireMay 16 18:00 ET

BioSyent Schedules Q1 2024 Earnings Release for May 16, 2024

MISSISSAUGA, Ontario, May 09, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. ("BioSyent", "the Company", TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2024 on

GlobeNewswireMay 9 16:30 ET

BioSyent to Attend Planet MicroCap Showcase

MISSISSAUGA, Ontario, April 23, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. ("BioSyent", TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Showcase in Las Vegas, Nevad

GlobeNewswireApr 23 17:45 ET

BioSyent Announces Extension of RepaGyn and Proktis-M Agreement

MISSISSAUGA, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. ("BioSyent", "the Company", TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. ("Bi

GlobeNewswireApr 15 16:31 ET